ERBB2 inhibition and heart failure. Cote GM, Sawyer DB, Chabner BA (2012) N Engl J Med 367: 2150-3 Chemotherapy and immunotherapy in metastatic colorectal cancer. Pohlmann PR, Mernaugh RL, Goff LW (2009) N Engl J Med 360: 2134; author reply 2135-6 Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) N Engl J Med 358: 1109-17 New drugs for rheumatoid arthritis. Olsen NJ, Stein CM (2004) N Engl J Med 350: 2167-79 ERBB2 inhibition and heart failure. Cote GM, Sawyer DB, Chabner BA (2013) N Engl J Med 368: 876 Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A, Bernards R (2012) Nature 483: 100-3 Tyrosine kinase inhibitors: why does the current process of clinical development not apply to them? Arteaga CL, Baselga J (2004) Cancer Cell 5: 525-31 EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans. Arteaga CL (2006) Cancer Cell 9: 421-3 HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Wang SE, Narasanna A, Perez-Torres M, Xiang B, Wu FY, Yang S, Carpenter G, Gazdar AF, Muthuswamy SK, Arteaga CL (2006) Cancer Cell 10: 25-38 ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Arteaga CL, Engelman JA (2014) Cancer Cell 25: 282-303 Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, Pavlick AC, Wang T, Hilsenbeck SG, Gutierrez C, Schiff R, Osborne CK, Chang JC (2013) J Clin Oncol 31: 1726-31 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ (2012) J Clin Oncol 30: 34-41 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) J Clin Oncol 23: 7889-96 Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) J Clin Oncol 26: 3743-8 Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. Hurwitz HI, Fehrenbacher L, Hainsworth JD, Heim W, Berlin J, Holmgren E, Hambleton J, Novotny WF, Kabbinavar F (2005) J Clin Oncol 23: 3502-8 High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM (2007) J Clin Oncol 25: 3644-8 Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Nazer B, Humphreys BD, Moslehi J (2011) Circulation 124: 1687-91 Cardiology patient page. Breast cancer chemotherapy and your heart. Unitt C, Montazeri K, Tolaney S, Moslehi J (2014) Circulation 129: e680-2 Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Circulation 105: 1551-4 Takayasu Arteritis: It Is Time to Work Together. Beckman JA (2015) Circulation 132: 1685-6 Treatment of HER2-positive breast cancer: current status and future perspectives. Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L (2011) Nat Rev Clin Oncol 9: 16-32 Progression of heart failure from AHA/ACC stage A to stage B or even C: can we all agree we should try to prevent this from happening? Lenihan DJ (2012) J Am Coll Cardiol 60: 2513-4 Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease. Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, Kok KB, Rovedatti L, Vossenkämper A, Ahmad N, Snoek SA, Vermeire S, Rutgeerts P, Jordan RE, MacDonald TT (2015) Gastroenterology 149: 1564-1574.e3 Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN (2001) Gastroenterology 120: 1713-9 Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Regales L, Gong Y, Shen R, de Stanchina E, Vivanco I, Goel A, Koutcher JA, Spassova M, Ouerfelli O, Mellinghoff IK, Zakowski MF, Politi KA, Pao W (2009) J Clin Invest 119: 3000-10 Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma. Feldman AS, He Y, Moore ML, Hershenson MB, Hartert TV (2015) Am J Respir Crit Care Med 191: 34-44 Efficacy of cetuximab in the treatment of Menetrier's disease. Fiske WH, Tanksley J, Nam KT, Goldenring JR, Slebos RJ, Liebler DC, Abtahi AM, La Fleur B, Ayers GD, Lind CD, Washington MK, Coffey RJ (2009) Sci Transl Med 1: 8ra18 HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation. Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA, Riely GJ, Kris MG, Miller VA, Ladanyi M, Politi K, Pao W (2012) Cancer Discov 2: 922-33 Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Johnson DB, Estrada MV, Salgado R, Sanchez V, Doxie DB, Opalenik SR, Vilgelm AE, Feld E, Johnson AS, Greenplate AR, Sanders ME, Lovly CM, Frederick DT, Kelley MC, Richmond A, Irish JM, Shyr Y, Sullivan RJ, Puzanov I, Sosman JA, Balko JM (2016) Nat Commun 7: 10582 Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113: E6849-E6858 Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Wang SE, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL (2009) Cancer Res 69: 475-82 Regulation of ERBB2 receptor by t-DARPP mediates trastuzumab resistance in human esophageal adenocarcinoma. Hong J, Katsha A, Lu P, Shyr Y, Belkhiri A, El-Rifai W (2012) Cancer Res 72: 4504-14 Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Reyzer ML, Caldwell RL, Dugger TC, Forbes JT, Ritter CA, Guix M, Arteaga CL, Caprioli RM (2004) Cancer Res 64: 9093-100 Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J (2010) Cancer Res 70: 299-308 Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL (2013) Cancer Res 73: 6013-23 Optical metabolic imaging identifies glycolytic levels, subtypes, and early-treatment response in breast cancer. Walsh AJ, Cook RS, Manning HC, Hicks DJ, Lafontant A, Arteaga CL, Skala MC (2013) Cancer Res 73: 6164-74 An antibody that locks HER3 in the inactive conformation inhibits tumor growth driven by HER2 or neuregulin. Garner AP, Bialucha CU, Sprague ER, Garrett JT, Sheng Q, Li S, Sineshchekova O, Saxena P, Sutton CR, Chen D, Chen Y, Wang H, Liang J, Das R, Mosher R, Gu J, Huang A, Haubst N, Zehetmeier C, Haberl M, Elis W, Kunz C, Heidt AB, Herlihy K, Murtie J, Schuller A, Arteaga CL, Sellers WR, Ettenberg SA (2013) Cancer Res 73: 6024-35 Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Cancer Res 62: 4132-41 Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Chakrabarty A, Bhola NE, Sutton C, Ghosh R, Kuba MG, Dave B, Chang JC, Arteaga CL (2013) Cancer Res 73: 1190-200 Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL (2001) Cancer Res 61: 8887-95
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.